love the down ramping here. what seems to be the problem? R&D has been the major consumer of funds. I agree a contract/revenue is imperative but a CR will help IMHO
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%